Continuation Study of the Oral AKT Inhibitor GSK2110183

Exclusion Criteria

• •Permanent discontinuation of GSK2110183 in the parent study due to toxicity or disease progression.
• •Concomitant use of any type of anti-cancer treatment other than studied in the parent protocol.
• •Local access to commercially available GSK2110183.
• •Current use of a prohibitive medication(s)
• •Current use of anticoagulants
• •Any unresolved toxicity greater than Grade 2 , except for alopecia, (National Cancer Institute-Common Toxicity Criteria for Adverse Events \[NCI-CTCAE\], version 4.0) from parent study treatment at the time of transition to this study.
• •History of HIV infection.
• •Peripheral neuropathy greater than Grade 1
• •History of hepatitis B or C infection (subjects with evidence of cleared hepatitis B are permitted).
• •Evidence of severe or uncontrolled systemic diseases (e.g., unstable, or uncompensated respiratory, hepatic, renal, metabolic or cardiac disease).
• •QTcF interval greater than 500 msecs at the time of transition to this study.
• •Other clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block.
• •Evidence of current Class II, III, or IV heart failure as defined by the New York Heart Association \[NYHA, 1994\] functional classification system at the time of transition to this study.
• •Symptomatic or untreated leptomeningeal, CNS or brain metastases or spinal cord compression at the time of transition to this study.
• •Lactating female or female who becomes pregnant prior to transition to this study.
• •Previously diagnosed diabetes mellitus Type I. Subjects with Type II diabetes are allowed if entry criteria are fulfilled
• •Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions at the time of transition to this study that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigator or GSK Medical Monitor.